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» The treatment of chronic HCV patients is currently based 
on (pegylated)-Interferon and Ribavirin
- Significant side effects
- Not all infected patients can be treated 
- Significant costs of treatment (up to 30.000 USD per year)
- Long duration (up to 48 weeks)
» Sustained virus response rates are between 50 and 60%,
for genotype 1 only 43-46% 1,2
1. Fried M. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med., 
Vol. 347, 13, 13 Sep 2002.
2. Manns M.P. et al. PINF alfa-2b plus ribavirin compared with INF alfa-2b plus ribavirin for initial treatment 
for chronic hepatitis C: a randomized trial. Lancet, Vol. 358 (9286), Sep 2001
Chronic Hepatitis C: Standard of Care
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» Stronger, broader, quicker and more sustained 
CD4 and CD8 T-cell responses in self-limited course of acute 
hepatitis C
» Response to antiviral therapy may be associated with increased 
T-cell responses
» Viral persistence in chronic hepatitis C is associated with 
immune evasion
? impaired function of HCV-specific T-cells
? mutational T-cell epitope escape
» Chimp models
Diepolder 1995, Missale 1996, Rehermann 1996, Lamonaca 1999, Gruener
2000, Thimme 2001, Wedemeyer 2002, Lauer 2002&2004, Cox 2005, Boettler
2005, Spangenberg 2005,...
HCV: importance of T-cell responses
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Th 2 Cytokines
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C E1 NS5NS4NS3NS2E2
|--- Envelope   ---| |---------------------------- Non-structural proteins   --------------------------------|Core
The IC41 HCV vaccine: 
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Conservative (green) and non-conservative (red) amino acid exchanges in each 
position of the NS2-1073 peptide among the different genotypes of the Hepatitis 
C Virus. 
indicates the positions important for HLA binding or for the TCR receptor 
recognition.Fytili et al. ,Vaccines 2008
Sequence variability in the NS3-1073 CTL epitope
*
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G1 G2 G3 G4G5 G6
Cross-genotype recognition of twenty-eight
NS3-1073 peptide variants
IFN-γ ELISPOT USING T-CELLS INDUCED AGAINST WILDTYPE
In vitro T-cell line
Fytili et al. ,
Vaccines 2008

























































TREATMENT SCHEDULE AND STUDY DESIGN (IC41-201)
IC41-1: 60 chronic HCV patients, 




Phase II in 
non-
responders
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Interferon gamma ELIspot using frozen PBMC
Assay standard:
control cells



















ELISPOT: > 3x OVER BACKGROUND, AT LEAST 15 PER MIO. PBMC
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CD8+ and CD4+ T-cells




IC41 induces Th1/Tc1 type immune responses in 
non-responder patients






Firbas et al., 2006
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Results of concluded Phase II study –
IC41 already showed trend in efficacy
Group results of 1 Log 






































































PHASE  II NON RESPONDERS (IC41-1)
Class I responses of 
>10spots/200,000 are 





Phase II in 
non-
responders
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Evidence for mutational T-cell epitope escape in a 
patient responding to IC41-1 vaccination
* Published and 


































































Impaired recognition of an HCV T cell epitope 






























Phase II in 
non-
responders
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IC41-2: Combination with standard therapy
PEGINF/RBV



















6 vaccinations s.c. 
in 4 weeks intervals
Relapse rate wk  52 / 60 / 72
Weeks after start of
standard therapy
V visit
Immunological Assays wk 28 / 48 / 52 / 60 / 72
Patients with chronic hepatitis C of genotype I scheduled for standard treatment for 
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Sustained responders show a stronger and more 
frequent T-cell response – Target Population*


















































































































*Target Population N = 23, for 1 patient missing HCV-RNA data between V8–V10
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Conclusions from non-responder patients (IC41-1) 
and late add-on to PEG-IFN/RBV (IC41-2)
» favorable safety profile in chronic HCV patients
with or without PEG-IFN/RBV standard therapy
» optimal vaccine dose (2,5 mg peptides / 2,0 mg poly-L-Arg)
» Th1/Tc1 type responses in chronic HCV patients,
no apparent negative influence through PEG-IFN/RBV
» several transient 1 log Hepatitis C - RNA responders at 
optimal dose
» RNA responses associated with strongest CD8+ 
responses achieved
» T-cell immunogenicity requires optimization
(rate, strength, breadth, sustainability)
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s.c. i.d. i.d. + "imiquimod" -
lot H (AB) lot H (AB) lot H (AB) -











































































s.c. i.d. i.d. + "imiquimod" -
lot H (AB) lot H (AB) lot H (AB) -


























































































(lot H in-house 
mixture AB)
exp. scheme:
day 0, 14, 28,
42, 56, 70
s.c. or i.d.injection
day 7 after 6th inj.
IFN-g ELIspot
(spleen cells) 
day 29 after 6th inj
APC transfer
























In vivo CTL assay
IC41 i.d. 
+ „Imiquimod“






TEST APPLICATION SITES  ± IMIQUIMOD
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IC41-3 Study concluded January 2008
OPTIMAL VACCINATION SCHEDULE IN TREATMENT 
NAIVE PATIENTS
8 vaccinations*           
0
» 50 Chronic HCV patients,  treatment naive, HCV Genotype 1.
Desired subset with low viral load at baseline
» Endpoints: ? Decline in HCV-RNA
? T-cell response
» Status ? Participating countries: Romania, Poland, Germany
? End of recruitment on track for February 2007
» First vaccination on September 26 2006, first data Q2/2007
2 4 6 8 10 12 14 16 38week





Phase II in 
naïve 
patients
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Primary endpoint met – a weak, but statistically 
significant HCV-RNA reduction
OVERVIEW IC41-3 PHASE II DATA
Statistically
significant
0 2 4 6 8 10 12 14-2 16
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Conclusions from IC41 trials
» Favorable safety profile in chronic HCV patients
with or without PEG-IFN/RBV standard therapy
» Optimal vaccine dose / schedule identified
» Th1/Tc1 type responses in chronic HCV patients,
no apparent negative influence through PEG-IFN/RBV
» Antiviral activity demonstrated in patients with strongest 
CD8+ responses, and treatment group with optimal 
vaccination
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HCV therapeutic vaccination: Forward Strategy
Development of second generation vaccine
»More & better peptides (HLA-restriction, efficacy)
» Improved T-cell adjuvant (IC31®)
Future plans: combination therapy
» plus PEG-IFN/RBV
» plus novel small molecule inhibitor
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Overlapping set of synthetic 






Defined T-cell epitopes 
for therapeutic vaccines
Epitope Capture: 
Binding to human 
HLA receptors
Reacting with 








Identification of further T-cell peptides
Reviewed in
Scharnagl & Klade







T-CELL EPITOPE IDENTIFICATION PROGRAM 
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(from Day et al.)











(DR4 / Ipep 1650)
?
(Ipep1800, IVS)




















(DR4 / Ipep 1563)
B35Ipep 1799
A24(?)
(A2 no final data)











(B7 / Ipep 1506)









HLA-COVERAGE: 80-90% IN EUROPE, USA AND JAPAN
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» KLK: 
antimicrobial peptide H-KLKL5KLK-OH
? Type 2 immune responses (+ proteins)





? Type 1 induction
? Activation of APC (Dendritic Cells)










IC31®: a TLR agonist comprising two chemically 
defined biodegradable components
? Enhancement of 
antigen and ODN1a 
uptake by APC 
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Protective immunity of a novel TB subunit 
vaccine adjuvanted with IC31®
PRECLINICAL EVALUATION – SURVIVAL (GUINEA PIG)*
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Protectivity is linked to IFN- γ producing T-cells














































DEFINITION OF PROTECTION MARKERS (MOUSE MODEL)
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Induction of antigen-specific T-cells in humans 
vaccinated with the novel TB subunit vaccines
DATA FROM TB PHASE I STUDY: STRONG TH-1 INDUCTION
&
IFN-γ in T-cell supernatants 
(Ag85B/ESAT-6-specific ELISA;
Estimated Marginal Means)
Frequency of IFN-γ prod. T-cells 
(Ag85B/ESAT-6-specific ELISpot;
Estimated Marginal Means)
visit 6 months 6 monthsvisit
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Dramatic improvement of IC41 by replacing 
poly(Arg) with IC31® (IC410)
exp. scheme:




















IC41 lotK PD03127 IC410 -
HHD.2





































































































Ipep 87, 89 (rel.)
IFN-γ PRODUCTION
CD8+ T CELL EFFECTOR FUNCTION
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